🟢 Moderna Inc is trading 4.15% up today on new operating model, 2027-2028 product launch outlook, and favorable FDA flu vaccine data

Moderna Inc is trading 4.15% up now at $57.70, extending a sharp multi-day rally as investors react to the company’s new operating model, leadership restructuring aimed at supporting multiple product launches in 2027–2028, and favorable FDA briefing documents for its mFlusiva mRNA seasonal flu vaccine candidate.

• The FDA staff's supportive read on mFlusiva efficacy data for adults 65 and older and superior relative efficacy in adults aged 50 to 64 significantly de-risked the upcoming advisory committee meeting.
• The company also announced an updated operating model and leadership restructuring to manage three commercial franchises and prepare for up to three new product launches in 2027–2028.
• Management is set to showcase AI-driven R&D productivity and future growth strategies during the upcoming Science Day scheduled for June 25, 2026.